MIMEDX GROUP INC (MDXG)
US6024961012 - Common Stock
MDXG gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. MDXG has an excellent financial health rating, but there are some minor concerns on its profitability. MDXG has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
MDXG had positive earnings in the past year.
MDXG had a positive operating cash flow in the past year.
MDXG had negative earnings in 4 of the past 5 years.
In the past 5 years MDXG reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 33.62%, MDXG belongs to the top of the industry, outperforming 99.11% of the companies in the same industry.
Looking at the Return On Equity, with a value of 45.30%, MDXG belongs to the top of the industry, outperforming 98.75% of the companies in the same industry.
With an excellent Return On Invested Capital value of 24.79%, MDXG belongs to the best of the industry, outperforming 98.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 33.62% | ||
| ROE | 45.3% | ||
| ROIC | 24.79% |
ROA(3y)-3.57%
ROA(5y)-13.45%
ROE(3y)-11.49%
ROE(5y)-40%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of MDXG (23.92%) is better than 97.33% of its industry peers.
MDXG's Operating Margin of 18.49% is amongst the best of the industry. MDXG outperforms 95.72% of its industry peers.
MDXG's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 83.37%, MDXG belongs to the top of the industry, outperforming 87.88% of the companies in the same industry.
In the last couple of years the Gross Margin of MDXG has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.49% | ||
| PM (TTM) | 23.92% | ||
| GM | 83.37% |
OM growth 3Y29.31%
OM growth 5Y-0.07%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.46%
GM growth 5Y-1.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MDXG is creating value.
MDXG has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MDXG has more shares outstanding
The debt/assets ratio for MDXG has been reduced compared to a year ago.
2.2 Solvency
MDXG has an Altman-Z score of 15.28. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
MDXG has a better Altman-Z score (15.28) than 90.20% of its industry peers.
The Debt to FCF ratio of MDXG is 0.34, which is an excellent value as it means it would take MDXG, only 0.34 years of fcf income to pay off all of its debts.
MDXG's Debt to FCF ratio of 0.34 is amongst the best of the industry. MDXG outperforms 96.97% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that MDXG is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.10, MDXG is doing worse than 65.06% of the companies in the same industry.
Although MDXG does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.34 | ||
| Altman-Z | 15.28 |
ROIC/WACC2.35
WACC10.57%
2.3 Liquidity
MDXG has a Current Ratio of 4.10. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG has a Current ratio of 4.10. This is comparable to the rest of the industry: MDXG outperforms 45.81% of its industry peers.
A Quick Ratio of 3.53 indicates that MDXG has no problem at all paying its short term obligations.
MDXG has a Quick ratio of 3.53. This is comparable to the rest of the industry: MDXG outperforms 42.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.1 | ||
| Quick Ratio | 3.53 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 2900.00% over the past year.
Looking at the last year, MDXG shows a quite strong growth in Revenue. The Revenue has grown by 10.93% in the last year.
The Revenue has been decreasing by -2.19% on average over the past years.
EPS 1Y (TTM)2900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)10.93%
Revenue growth 3Y9.01%
Revenue growth 5Y-2.19%
Sales Q2Q%2.87%
3.2 Future
Based on estimates for the next years, MDXG will show a very strong growth in Earnings Per Share. The EPS will grow by 38.07% on average per year.
The Revenue is expected to grow by 11.61% on average over the next years. This is quite good.
EPS Next Y-5.01%
EPS Next 2Y-0.6%
EPS Next 3Y11.51%
EPS Next 5Y38.07%
Revenue Next Year7.98%
Revenue Next 2Y8.58%
Revenue Next 3Y10.13%
Revenue Next 5Y11.61%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 16.17, which indicates a correct valuation of MDXG.
96.79% of the companies in the same industry are more expensive than MDXG, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 28.81, MDXG is valued a bit cheaper.
MDXG is valuated quite expensively with a Price/Forward Earnings ratio of 28.64.
Based on the Price/Forward Earnings ratio, MDXG is valued cheaply inside the industry as 93.94% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 23.56. MDXG is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.17 | ||
| Fwd PE | 28.64 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MDXG is valued cheaply inside the industry as 95.19% of the companies are valued more expensively.
MDXG's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MDXG is cheaper than 96.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.87 | ||
| EV/EBITDA | 19.14 |
4.3 Compensation for Growth
MDXG has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.6%
EPS Next 3Y11.51%
5. Dividend
5.1 Amount
MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MIMEDX GROUP INC
NASDAQ:MDXG (11/15/2024, 10:00:55 AM)
9.055
-0.18 (-1.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.33B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.17 | ||
| Fwd PE | 28.64 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 33.62% | ||
| ROE | 45.3% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 18.49% | ||
| PM (TTM) | 23.92% | ||
| GM | 83.37% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.1 | ||
| Quick Ratio | 3.53 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)2900%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-5.01%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)10.93%
Revenue growth 3Y9.01%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y